Concepedia

L Derikx

LD

4

Publications

106

Citations

4

H-Index

2021

Active since

Affiliations

Radboud University Nijmegen(Current)

Institute of Genetics and Cancer

University of Edinburgh

Western General Hospital

Radboud University Medical Center

L Derikx is an author at Radboud University Nijmegen.

Publications per year

2021–2023

4

Publications

4

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Neil Chanchlani, Simeng Lin, Desmond Chee et al. · Journal of Crohn s and Colitis · 2021 · 45 citations · Full text

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts

L Derikx, Heather W Dolby, Nikolas Plevris et al. · Journal of Crohn s and Colitis · 2021 · 32 citations · Full text

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort

Beatriz Gros, Nikolas Plevris, Nathan Constantine‐Cooke et al. · United European Gastroenterology Journal · 2023 · 17 citations · Full text

Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis

Mathew Lyons, L Derikx, James Fulforth et al. · Alimentary Pharmacology & Therapeutics · 2022 · 12 citations · Full text

Rows per page

1–4 of 4